Drug intelligence / Profile preview

BEY-4101

Development stage: Preclinical
Lead developer: BeyondBio
Modality: Small Molecules

Overview

BEY-4101 is a small molecule drug developed by Beyondbio, Inc. It functions as a CLK modulator, specifically targeting Clk dual-specificity kinases. This drug is currently in preclinical development and is being investigated for its potential therapeutic applications in hematologic neoplasms and solid tumors.

Targets

CLK4CLK3 (CDC-like kinase 3)CLK2 (CDC-like kinase 2)CLK1 (CDC-like kinase 1)

Beyond the preview

Go deeper on BEY-4101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEY-4101.

Explore the full profile